{
Sebastian Vogel

People

}
001122334455554433221100
001122334455554433221100

R&S shares rise after UBS raises price target to 24.70 francs

R&S shares benefited from an increased price target of CHF 24.70 from UBS, up from CHF 23.70, while maintaining a buy recommendation. The stock rose 5.7% to 19.50 francs amid a positive market, despite a year-to-date decline of 1.1%. Analyst Sebastian Vogel cited favorable demand and sales growth forecasts, although he anticipates slightly lower price support for the 2025 financial year.
finanzen.ch
Swiss Franc CHE Sebastian Vogel
Finance & Economy, Market Report
12:07 18.03.2025

R&S shares rise after UBS raises price target amid strong demand

R&S shares surged 5.7% to 19.50 francs following UBS's price target increase from 23.70 to 24.70 francs, maintaining a buy recommendation. The analyst cited a favorable demand environment and positive sales growth forecasts, despite expectations of slightly lower price support in 2025.
MarketScreener
Swiss Franc CHE Sebastian Vogel
Finance & Economy, Market Report
10:15 18.03.2025

ubs downgrades galenica stock to neutral amid regulatory concerns

UBS analyst Sebastian Vogel has downgraded Galenica AG's stock rating from Buy to Neutral, lowering the price target to CHF83.00 from CHF83.50 due to concerns over upcoming regulatory changes affecting over-the-counter drug distribution by fiscal year 2028. While long-term revenue potential remains positive, the winding down of the flu season reduces immediate performance catalysts. UBS projects a 3.0% dividend yield for fiscal year 2026, aligning with the company's historical average, indicating limited short-term stock performance drivers.
Investing.com
Swiss Franc Galenica AG CHE Sebastian Vogel
Finance & Economy, Market Report
07:29 14.03.2025

UBS lowers DocMorris price target amid tough competition and consumer hesitance

UBS has downgraded the price target for DocMorris from 25 to 16 francs, maintaining a "Sell" rating. Analyst Sebastian Vogel cites ongoing tough competition and slow shifts in consumer behavior as reasons for revising market share assumptions and lowering estimates for operating margin and earnings per share.
boerse.de
Swiss Franc Zur Rose Group AG DEU Sebastian Vogel
Finance & Economy, Market Report
08:01 07.02.2025

ubs cuts docmorris price target to 16 francs maintains sell rating

UBS has reduced its price target for DocMorris from 25 to 16 francs, maintaining a "Sell" rating. Analyst Sebastian Vogel cites ongoing tough competition and slow changes in consumer habits as reasons for the downward revision of market share assumptions, adjusted operating margin, and earnings per share estimates.
aktiencheck.de
Swiss Franc DEU Sebastian Vogel
Finance & Economy, Market Report
07:01 07.02.2025

UBS maintains sell rating for Zur Rose Group with target price of 25 francs

UBS has maintained a "Sell" rating for DocMorris, setting a target price of 25 francs. Analyst Sebastian Vogel noted that the online pharmacy fell short of overall expectations, particularly in its prescription business, which was a significant disappointment.
boerse.de
Swiss Franc Zur Rose Group AG CHE Warren Buffett Hubert Dichtl Sebastian Vogel Thomas Müller Show more
Finance & Economy, Market Report
12:39 21.01.2025

ubs maintains sell rating for docmorris with target price of 25 francs

UBS has maintained a 'Sell' rating for DocMorris, setting a target price of 25 francs. Analyst Sebastian Vogel noted that the online pharmacy fell short of overall expectations, particularly in its prescription business, which was a significant disappointment.
MarketScreener
Swiss Franc DEU Sebastian Vogel
Finance & Economy, Market Report
12:26 21.01.2025

UBS cuts DocMorris price target to 25 francs maintains sell rating

UBS has reduced its price target for DocMorris from 27 to 25 francs, maintaining a "Sell" rating. Analyst Sebastian Vogel noted that the online pharmacy's recent statements indicate a slowdown in growth for prescription drugs in the German market in the near term.
ch.marketscreener.com
Swiss Franc UBS SA DEU Sebastian Vogel
TradFi, Market Report
11:39 17.10.2024

UBS reduces DocMorris price target to 25 francs maintains sell rating

UBS has reduced its price target for DocMorris from 27 to 25 francs, maintaining a "Sell" rating. Analyst Sebastian Vogel noted that the online pharmacy's recent statements indicate a weaker growth outlook for prescription drugs in the German market in the near term.
aktiencheck.de
Swiss Franc UBS SA DEU Sebastian Vogel
TradFi, Market Report
10:52 17.10.2024

UBS downgrades DocMorris price target amid concerns over growth in Germany

UBS has downgraded its price target for DocMorris from 27 to 25 francs, maintaining a "Sell" rating. Analyst Sebastian Vogel noted that the online pharmacy's recent statements indicate a weaker growth outlook for prescription drugs in the German market in the near term.
boerse.de
Swiss Franc Zur Rose Group SA CHE DEU Sebastian Vogel Hubert Dichtl Thomas Müller Warren Buffet Show more
TradFi, Market Report
10:52 17.10.2024
Trending
Subcategory
Stock Market Updates Corporate News Industry Trends Global Trade Developments Global Financial Events Central Bank Actions Banking Regulations Retail and Consumer Goods Finance Mergers & Acquisitions Industry Mergers & Acquisitions Startups & Entrepreneurship Inflation and Monetary Impact Government Economic Policies Domestic Politics CEO Changes Market Analysis and Predictions Workplace Trends Government Policies Supply Chain Management Financial Scams and Security
Countries:
USA CHN GBR CHE DEU IND FRA JPN CAN VNM AUS MEX ITA ARE SGP ESP THA TWN NLD MYS
Companies:
Tesla, Inc. Apple Inc. Barclays PLC JPMorgan Chase & Co. Deutsche Bank Money Market PP Credit Suisse Strategic Income I The Goldman Sachs Group, Inc. Berkshire Hathaway Inc. UBS Group AG BNP Paribas SA Banco Santander, S.A. Lloyds Banking Group plc SpaceXCoin USD Jenoptik AG Air France-KLM Bank of America Corporation Amazon.com, Inc. NVIDIA Corporation Infineon Technologies AG Banco BPM S.p.A.
Currencies:
United States Dollar Euro British Pound Sterling Swiss Franc Japanese Yen Indian Rupee Chinese Yuan Canadian Dollar Vietnamese Đồng South Korean Won Australian Dollar Thai Baht Singapore Dollar Indonesian Rupiah Mexican Peso Hong Kong Dollar Offshore Chinese Yuan New Zealand Dollar Cambodian Riel Myanmar Kyat
People:
Donald Trump Elon Musk JD Vance Sergio Ermotti Warren Buffett Mark Haefele Jennifer Piepszak Ursula von der Leyen Olivier Calvet Scott Bessent George Saravelos Karoline Leavitt Francois Xavier Bouvignies Joseph Spak Robin Leopold Susan P. Crawford Greg Rubini Narendra Modi Joe Biden Petra Kaltenbach

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.